Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
AssigneeUniversity of Kentucky Research Foundation
InventorsPeter A. Crooks, Linda P. Dwoskin, Alain Ravard
Life of this patent
Estimating the term…
Abstract
Nicotine analogs that have nicotinic receptor antagonist properties. These compounds have been shown to competitively inhibit dopamine release induced by nicotine. The nicotine analog compounds are useful in the treatment of nicotine abuse, smoking cessation therapy, as an antidote for nicotine intoxication, treatment of cognitive disorders such as Alzheimer's disease and for the treatment of Parkinson's disease.
Claims13
A compound of the following formula:
- ##STR3## wherein R=branched alkyl with 4-19 carbon atoms, cycloalkyl, N-alkenyl or alkenyl with 4-19 carbon atoms, and N-alkynyl or branched alkynyl with 4-19 carbon atoms;
- and X=Cl.sup.-, I.sup.-, HSO.sub.4.sup.-, 1/2SO.sub.4 2.sup.-.
A method of antagonizing the nicotinic receptor comprising administering a pharmaceutically effective amount of a compound according to the following formula:
- ##STR4## wherein R=N-alkyl or branched alkyl with 2-19 carbon atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 carbon atoms, and N-alkynyl or branched alkynyl with 2-19 carbon atoms;
- and X=Cl.sup.-, Br.sup.-, I.sup.-, HSO.sub.4.sup.-, 1/2SO.sub.4 2.sup.- to a host in need of said treatment.
A method of treatment of a condition selected from the group consisting of abuse of nicotinic agonist drugs, smoking addiction, and nicotine intoxication comprising administering a pharmaceutically effective amount of a compound according to the following formula:
- ##STR5## wherein R=N-alkyl or branched alkyl with 2-19 carbon atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 carbon atoms, and N-alkynyl or branched alkynyl with 2-19 carbon atoms;
- and X=Cl.sup.-, Br.sup.-, I.sup.-, HSO.sub.4.sup.-, 1/2SO.sub.4 2.sup.- to a host in need of said treatment.
A method of treatment of Alzheimer's disease comprising administering a pharmaceutically effective amount of a compound of the following formula:
- ##STR6## wherein R=N-alkyl or branched alkyl with 2-19 carbon atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 carbon atoms, and N-alkynyl or branched alkynyl with 2-19 carbon atoms;
- and X=Cl.sup.-, Br.sup.-, I.sup.-, HSO.sub.4.sup.-, 1/2SO.sub.4 2.sup.- to a host in need of said treatment.
A method of treatment of Parkinson='s disease comprising administering a pharmaceutically effective amount of a compound according to the following formula:
- ##STR7## wherein R=N-alkyl or branched alkyl with 2-19 carbon atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19 4-19 carbon atoms, and N-alkynyl or branched alkynyl with 2-19 carbon atoms;
- and X=Cl.sup.-, Br.sup.-, I.sup.-, HSO.sub.4.sup.-, 1/2SO.sub.4 2.sup.- to a host in need of said treatment.
Dependencies are inferred from the claim text.